From The Stage

The Power of Being NYCE

Dr. Jim McNally
Posted by Dr. Jim McNally / / Gene Therapy, Industry Update

A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the promising results.

Vector Innovation to Improve Gene Therapy Safety: A Credit to Scientific Tenacity

Dr. Jim McNally
Posted by Dr. Jim McNally / / BioAgilytix Insight, Gene Therapy

A new clinical trial by St. Jude Children’s Research Hospital for the treatment of SCID-X1 highlights a major advancement in gene therapy safety over recent years, in this case spurred by scientists who were courageous enough to push forward the development of safer vectors to overcome serious adverse events (SAEs) that were resulting from the previous generation of gene therapies developed for SCID-X1.